Latest News and Developments About RA
SetPoint Medical has launched a pilot trial to assess the safety and efficacy of a bioelectronics device in patients, who are suffering from rheumatoid arthritis.
Valencia, CA-based SetPoint's approach toward treating RA is designed to supplement the body's natural inflammatory reflex by providing "built-in" therapy and is intended to improve safety compared with drugs or biologic solutions.
“We’re trying to use bioelectric medicine, or little digital doses of electricity, which are pulses down the vagus nerve, to modulate this disease,” Anthony Arnold, CEO of SetPoint Medical, told MD+DI.
The technology is implanted in the left side of the neck, just above the collarbone, through an incision about one-inch long. Arnold said it’s a pretty routine procedure that can be performed in under an hour.
Initial research indicated that active electrical stimulation of the vagus nerve inhibits tumor necrosis factor (TNF) production in RA patients and significantly attenuates RA disease severity. In addition, no serious adverse side effects were reported.
More information: www.mddionline.com